# OnCo record paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023" ;
schema:name "Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)"@en ;
schema:description "Adding a cheap old antibody to the refractory-line tablet took median survival from 7.5 to 10.8 months, the largest gain in this setting since the setting existed."@en ;
schema:url ;
schema:dateModified "2026-09-24"^^xsd:date ;
schema:citation , ;
onco:tag "colorectal-evidence" ;
schema:sameAs ;
schema:datePublished "2023"^^xsd:gYear ;
schema:author "Prager GW, Taieb J, Fakih M, et al." ;
onco:related , ;
onco:cancers ;
onco:sections ;
onco:technologies , ;
onco:targets ;
onco:drugs , ;
onco:companies , ;
onco:terms ;
onco:trials ;
onco:people , , ;
onco:journals .